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Results

Introduction
• OVCA is the most deadly form of gynecological cancers1
• High rate of OVCA is correlated to the absence of screening
which leads to diagnosis of disease at advanced stages2
• High fatality rate of OVCA is due to late presentation of
disease, cancer persistence, and chemotherapy resistance3
• A key approach to combatting cancer is through activation
of the apoptosis pathway4
• Momordica charantia, commonly known as the bitter melon,
comes from the family Cucurbitacae5
• Momordica charantia is reported to have anti-oxidant, antiinflammatory, anti-cancer, anti-diabetic, anti-bacterial, antiobesity, and immunomodulatory activities 5
• Previous studies have shown these anti-cancer properties
on various forms of cancer4
• Specifically, BG-4, a specific peptide found in Momordica
charantia was shown to inhibit proliferation in colon cancer
cells by promoting apoptosis through down-regulation of
anti-apoptotic proteins, up-regulation of pro-apoptotic
proteins, and modification of cell cycle proteins4

Cell cycle markers

Effect of BG-4 on OVCA cell proliferation

(a)
Figure 1. BG-4 purified from Momordica
chrantia
caused
dose-dependent
cytotoxicity in COV318 OVCA cells. BG-4
treatment led to a decrease in viable cell
count by 19.8% at 250 μg/mL. Mean values
represented as bars with different letter(s)
are statistically different from each other
(P<0.05, n=2).

Figure 2. BG-4 purified from Momordica
chrantia
caused
dose-dependent
cytotoxicity in 1AP (A27801AP) OVCA cells.
BG-4 treatment led to a decrease in viable cell
count by 65.1% at 250 μg/mL. Mean values
represented as bars with different letter(s)
are statistically different from each other
(P<0.05, n=2).

(b)

Figure 4. BG-4 modified expressions of cell cycle proteins in 1AP OVCA cell
line). BG-4 increased the expression of p21 (a) leading to a reduction in
expression of CDK2 (b). All analyses were done in at least two independent
replicates. Mean values represented as bars with different letter(s) are statistically
different from each other (P<0.05, n=2)

Effect of BG-4 on apoptotic markers

Objectives
The objective of this research is to determine the ability of BG-4 to cause
cytotoxicity to ovarian cancer cells (A27801AP and COV318) and determine
the mechanism involved by measuring proteins associated with apoptosis.
Specifically,

(a)

(b)

o Effect of BG-4 on Bcl-2 and XIAP (anti-apoptotic proteins)
o Effect of BG-4 on BAX and capsase-3 (pro-apoptotic proteins)
o Effect of BG-4 on p21 and CDK2 (cell cycle proteins)

Experimental Design

Methods

Cell Lines and Culture
Cell Proliferation Assay
Western Blotting
Apoptosis Assay

(c)

(d)

Figure 3. BG_4 modified expression of apoptotic proteins. (a) BG-4 promoted
apoptosis by increasing caspase-3 (a) and BAX (b) leading to a reduced expression of
XIAP (c) and no change in expression of Bcl-2 (d). Mean values represented as bars
with different letter(s) are statistically different from each other (P<0.05, n=2).
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BG-4 induces apoptosis in OVCA 1AP cells as measured by flow cytommetry.
Quantification of OVCA cells undergoing apoptosis as a result of BG-4 treatment. The
live cells were from 89.955% (untreated) to 73.92% and 68.83% for 125 μg/mL and
250 μg/mL treatment, respectively. Early apoptotic cells were from 7.10%
(untreated) to 20.99% and 23.95% for 125 μg/mL and 250 μg/mL treatment,
respectively. Late apoptotic cells were from 1.965% (untreated) to 3.72% and 5.37%
for 125 μg/mL and 250 μg/mL treatment, respectively. Necrotic cells were from
0.98% (untreated) to 1.36% and 1.81% for 125 μg/mL and 250 μg/mL treatment,
respectively. Mean values represented as bars with different letter(s) are statistically
different from each other (P<0.05, n=2).

Conclusions

• BG-4 from Momordica charantia possesses anti-cancer properties
• BG-4 has the capability of activating apoptosis in human ovarian
cancer cells
• The findings support the idea for potential use of BG-4 as an
ovarian cancer therapeutic agent and should be further studied
using in vivo models of ovarian carcinogenesis
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